Inventera to file for approval of MRI contrast agent for musculoskeletal imaging in Q4, targeting a turn to profit in 2028
Predicted impact: Medium
Planned Q4 approval filing and 2028 profit target for pre-revenue company; timeline far off.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.